PatIntNews

Today S*BIO and Tragata have announced that S*BIO has granted a worldwide exclusive license to Tragara to develop and commercialize its novel multi-kinase inhibitor SB1317.

In view of the foregoing, S*BIO will receive payments up to US$112.5 million, under the terms of the agreement, which includes an upfront fee, development and sales milestone payments and up to double-digit royalties. Additionally, S*BIO will receive research fees to perform certain preclinical activities for Tragara under a defined workplan. Under the agreement, Tragara is responsible for all IND enabling, development and commercialization activities.

Novel Multi-kinase Inhibitor SB1317 is an orally-available novel compound with excellent pharmacological and pharmaceutical properties. Initially, its development will be focused on the treatment of hematologic malignancies. Tragara will also explore the therapeutic potential of the compound's activity in solid tumors.

"Our entire Tragara team is excited about adding SB1317 to our product pipeline," said Thomas M. Estok, President and CEO of Tragara. "S*BIO successfully identified a promising compound for the treatment of hematological and potentially solid tumors and we look forward to further profiling the compound and moving it toward clinical development."

"We are pleased to work with Tragara in rapidly advancing SB1317 through IND enabling studies to the clinic. We chose Tragara as a partner due to a combination of their experience, exciting clinical development plans and commitment to speed. Together we will determine the full breadth of the compound's competitive advantages in a series of preclinical profiling studies prior to Tragara advancing this product through parallel tracks of clinical development," said Dr. Jan-Anders Karlsson, CEO of S*BIO.